Clinical Trials, Drug Development

AtreMorine: A Biotechnological / Nutraceutical product for Parkinson’s

By EuroEspes Biotechnology

AtreMorine is a novel biopharmaceutical compound obtained by means of nondenaturing biotechnological procedures from the structural components of the Vicia faba L plant, for the prevention and treatment of Parkinson´s disease (PD) and related disorders.

E-PodoFavalin-15999 extract is the structural base of AtreMorine and a natural source of L-DOPA, with an average concentration of 25 mg per gram of AtreMorine; it also contains a plethora of other bioactive substances as vegetal proteins, unsaturated fatty acids, minerals and vitamins, vegetal fibre, starch, vegetal pigments (carotenes) and vegetal sterols (phytosterols).

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.